Fig. 1.
Schematic representation of molVTP and of the different targeting moieties that have been investigated to selectively target PS to the tumor vasculature, for improving selectivity and efficacy of cancer treatment: (a) small peptide, (b) affibody, (c) single chain variable fragment (scFv), (d) antigen-binding fragment (Fab), (e) small immunoprotein (SIP), (f) antibody (IgG), and (g) nanocarrier systems
